Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671979 | 0.85 | HTT (0.35) | SLC6A2SLC6A4OPRM1MEN1KMT2A | |
| SCHEMBL2671873 | 0.81 | LMNA (0.37) | SLC6A2SLC6A4SLC6A3POLBMAPT | |
| SCHEMBL2672661 | 0.75 | HCRTR1 (0.35) | MEN1KMT2AMAPT | |
| SCHEMBL23672489 | 0.73 | SLC6A2 (0.32) | SLC6A2SLC6A4KMT2AMAPTTSHR | |
| SCHEMBL6877016 | 0.71 | MAPK8 (0.39) | — | |
| SCHEMBL29129339 | 0.70 | KMT2A (0.45) | POLBMEN1KMT2AMAPTTSHR | |
| SCHEMBL5659950 | 0.70 | OPRK1 (0.39) | — | |
| SCHEMBL16216060 | 0.70 | MEN1 (0.51) | SLC6A2SLC6A4OPRM1MEN1KMT2A | |
| SCHEMBL1933310 | 0.70 | MEN1 (0.51) | SLC6A2SLC6A4OPRM1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2567796 | 0.69 | CTSD (0.44) | SLC6A2SLC6A4KMT2AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723381-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | CYP2E1, UGT1A1, SLC26A4 | SLC6A2 1745/4885SLC6A4 888/4885OPRM1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.